The first U.S. Phase I clinical trial to evaluate CRISPR-Cas9-edited T cells in humans with advanced cancer has reported that the patients experienced no negative side effects, and that the engineered T cells persisted in their bodies for months. The trial included three advanced cancer patients who received T cells that had been engineered using […]
The post June Lab Delivers CRISPR Safety Message in Cancer Clinical Trial appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: June Lab Delivers CRISPR Safety Message in Cancer Clinical Trial